ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
IMMUCELL CORP /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$10.51−0.24 (-2.23%)
Close on Oct 19, 2026
- Market cap
- $96.58M
- P/E (TTM)
- 131.4
- Dividend yield
- –
IMMUCELL CORP /DE/ revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Segment, Scours [Member] | $27.45M | $26.31M | – | – | – | – | – | – | – | 99.3% | +4.3% |
| Corporate Segment, Mastitis [Member] | $196.39K | $178.92K | – | – | – | – | – | – | – | 0.7% | +9.8% |
| First Defense [Member] | – | – | – | – | $18.93M | $15.07M | – | – | – | – | – |
| Unallocated [Member] | – | – | – | – | $309.88K | $269.76K | – | – | – | – | – |
| Scours [Member] | – | $26.31M | $17.29M | $18.41M | $18.93M | – | – | – | – | – | – |
| Mastitis [Member] | – | $178.92K | $177.74K | $154.56K | $143.28K | – | – | – | – | – | – |
| Other [Member] | – | – | – | $1.46K | $166.60K | – | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Segment, Scours [Member] | $7.89M | $4.78M | – | – | – | – | – | – | – | +65.1% |
| Corporate Segment, Mastitis [Member] | -$2.92M | -$4.04M | – | – | – | – | – | – | – | -27.7% |
| Re-Tain [Member] | – | – | – | – | -$4.45M | -$4.07M | – | – | – | – |
| First Defense [Member] | – | – | – | – | $6.55M | $4.56M | – | – | – | – |
| Unallocated [Member] | – | – | – | – | -$1.85M | -$1.87M | – | – | – | – |
| Scours [Member] | – | $4.78M | $1.38M | $5.72M | $6.55M | $4.56M | – | – | – | – |
| Mastitis [Member] | – | -$4.04M | -$4.85M | -$5.62M | -$4.41M | -$4.05M | – | – | – | – |
| Other [Member] | – | -$2.38M | -$2.28M | -$2.40M | -$1.89M | -$1.89M | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| First Defense product line [Member] | – | $26.31M | $17.29M | $18.41M | $18.93M | $15.07M | $13.24M | $10.66M | $9.81M | – | – |
| Other animal health [Member] | – | $178.92K | $177.74K | $156.01K | $309.88K | $269.76K | $344.88K | $298.93K | $423.79K | – | – |
| Other [Member] | – | – | – | – | – | – | $133.60K | $24.10K | $192.80K | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States [Member] | – | – | – | – | – | – | $12.19M | $9.56M | $8.63M | – | – |
| Other [Member] | – | $3.60M | $1.52M | $1.55M | $2.62M | $1.70M | $1.53M | $1.43M | $1.80M | – | – |
| United States | – | $22.89M | $15.95M | $17.02M | $16.62M | $13.64M | $12.19M | – | – | – | – |
From the segment and revenue-disaggregation notes of Immucell's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.